Table 1.
Description of the study population.
| Inclusion | N = 42 |
|---|---|
| Sex | F: 14 (33.3%), M: 28 (66.7%) |
| Age | 39.0 [31.0–49.0] |
| Type of tuberculosis | Lymph nodes: 17 (40.5%) |
| Bone: 5 (11.9%) | |
| Lymph nodes + Bone: 6 (14.3%) | |
| Lymph nodes + Lung: 6 (14.3%) | |
| Bone + Lung: 4 (9.5%) | |
| Lymph nodes + Bone + Lung: 4 (9.5%) | |
| Associated disease | Diabetes Type II: 3 (7.1%) |
| Chronic inflammatory disease (controlled): 2 (4.8%) | |
| Cancer: 1 (2.4%) | |
| Temperature | 37.0 [36.8–37.2] |
| Body weight, kg | 63.0 [55.0–80.0] |
| Symptoms | Sweats: 13 (31.0%): Cough: 7 (16.7%); Pain related to tuberculosis: 23 (54.8%) |
| Biology | Hb: 12.1 [11.1–13.7]; WBC: 7.1 [5.6–9.0]; Platelets: 309.0 [265.0–371.0] |
| ALAT: 25.0 [16.0–38.0]; ASAT: 26.0 [21.0–37.0]; PAL: 96.0 [73.0–126.0]; ⋎GT: 64.0 [29.0–107.0] | |
| Creatinin: 70.0 [61.0–83.0] | |
| CRP: 19.0 [8.5–79.0] | |
| Microbiology | Lung: positive in 10/34 (29.4%) patients |
| Lymph nodes: positive in 11/21 (52.4%) patients | |
| Bone: positive in 11/14 (78.6%) patients | |
| Other: positive in 6/9 (66.7%) patients | |
| Imaging data (other than PET) | Thoracic radiography: abnormal in 9/31 (29.0%) patients |
| Thoracic CT: abnormal in 28/33 (84.8%) patients | |
| Abdominal CT: abnormal in 13/27 (48.1%) patients | |
| Bone MRI: abnormal in 19/19 (100%) patients | |
| Antibiotherapy | Isoniazide: 100% of patients |
| Rifampicine: 97.6% of patients | |
| Ethambutol: 95.2% of patients | |
| Pyrazinamide: 95.2% of patients | |
| Moxifloxacin: 2.4% of patients | |
| Treatment duration (months) | 9.0 [9.0–12.0] |
| Treatment observance > 80% | 34/36 (94.4%) patients |
Results are expressed as median [IQR] or n (%).